IP Library › Granted Patent US 12,580,059
Granted Patent B2
US 12,580,059 · App. 17/738,869 · Granted Mar 17, 2026

IV compounding systems and methods

Inventors: Larry McCutchan (Allison Park, PA); Stanley Mamula (Oakmont, PA); Charles Marsh (Cranberry Township, PA)
Assignee: Omnicell, Inc.
G16H20/10A61J3/002A61M5/00G16H40/20G06F3/0482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,580,059
App. No.
17/738,869
Granted
Mar 17, 2026
Kind
B2
Abstract

Systems and methods of compounding of medication include a user interface that enables efficient design of compounding workflows and protocols. A user can select a workflow type from a number of workflow types differentiated at least in part by the vehicle in which a compounded pharmaceutical is to be delivered, and the user may also specify a compounding device. Options are presented and the steps of a workflow in accordance with the workflow type and options is displayed and updated in real time as options are selected. A protocol can be constructed by inserting information into the workflow based on a specification of a particular pharmaceutical to be compounded.

Claims (67)

1 . A method of compounding a medication, the method comprising:

presenting, at a user interface presented on an electronic display, a list of a number of workflow types differentiated at least in part by a kind of delivery vehicle in which a completed compounded pharmaceutical is to be delivered;

receiving, via a user input device, a first user selection of one of the number of workflow types;

presenting, at the user interface, a list of a number of compounding device types that are available for use with the selected workflow type;

receiving, via the user input device, a second user selection of one of the number of compounding device types;

presenting, at the user interface, a number of options applicable to compounding a pharmaceutical on the selected compounding device type into the delivery vehicle of the selected workflow type;

receiving, via the user input device, a third user selection of one or more of the options;

presenting, in the user interface, an automatically constructed workflow for compounding a pharmaceutical into the delivery vehicle of the selected workflow type on the selected compounding device type;

receiving, via the user input device, a fourth user selection that specifies a particular pharmaceutical to be compounded according to the constructed workflow;

receiving an automatically constructed compounding protocol constructed from the constructed workflow;

causing the compounding protocol to be transmitted to a robotic compounding device of the selected compounding device type; and

causing the robotic compounding device to compound the specified pharmaceutical into the delivery vehicle of the selected workflow type in accordance with the compounding protocol, wherein during compounding the specified pharmaceutical, the robotic compounding device verifies that the delivery vehicle matches the selected workflow type, transfers a correct volume of the specified pharmaceutical, into the delivery vehicle, and verifies that the correct volume of the specified pharmaceutical has been transferred to the delivery vehicle.

2 . The method of claim 1 , wherein:

causing the specified pharmaceutical to be compounded into the delivery vehicle of the selected workflow type comprises compounding the specified pharmaceutical into a container suitable for intravenous delivery of the specified pharmaceutical.

3 . The method of claim 1 , wherein:

causing the specified pharmaceutical to be compounded into the delivery vehicle of the selected workflow type comprises compounding the specified pharmaceutical into a container suitable for oral liquid delivery of the specified pharmaceutical.

4 . The method of claim 1 , wherein:

the workflow comprises placeholders for information to be determined by a specific pharmaceutical to be compounded according to the constructed workflow.

5 . The method of claim 1 , further comprising:

saving the compounding protocol to a workflow database.

6 . The method of claim 1 , wherein:

causing the specified pharmaceutical to be compounded into the delivery vehicle of the selected workflow type comprises causing a compounding robot to perform at least one step of the compounding protocol.

7 . The method of claim 1 , wherein:

causing the specified pharmaceutical to be compounded into the delivery vehicle of the selected workflow type comprises causing a compounding robot to perform each step of the compounding protocol.

8 . The method of claim 1 , wherein:

causing the specified pharmaceutical to be compounded into the delivery vehicle of the selected workflow type comprises:

receiving user credentials from a reviewing party; and

receiving a verification confirmation associated with the compounding protocol from the reviewing party.

9 . The method of claim 8 , wherein:

causing the specified pharmaceutical to be compounded into the delivery vehicle of the selected workflow type further comprises causing verification information to be presented on a remote device upon receiving the user credentials.

10 . The method of claim 1 , further comprising:

automatically generating the constructed workflow based on the first user selection, the second user selection, the third user selection, and the fourth user selection.

11 . A system for pharmaceutical compounding, comprising:

one or more processors;

an electronic display; and

memory holding instructions that, when executed by the one or more processors, cause the system to:

present, at a user interface presented on the electronic display, a list of a number of workflow types differentiated at least in part by a kind of delivery vehicle in which a completed compounded pharmaceutical is to be delivered;

receive, via a user input device, a first user selection of one of the number of workflow types;

present, at the user interface, a list of a number of compounding device types;

receive, via the user input device, a second user selection of one of the number of compounding device types;

present, at the user interface, a number of options applicable to compounding a pharmaceutical on the selected compounding device type into the delivery vehicle of the selected workflow type;

receive, via the user input device, a third user selection of one or more of the options;

present, in the user interface, an automatically constructed workflow for compounding a pharmaceutical into the delivery vehicle of the selected workflow type on the selected compounding device type;

receive, via the user input device, a fourth user selection that specifies a particular pharmaceutical to be compounded according to the constructed workflow;

receive an automatically constructed compounding protocol constructed from the constructed workflow;

cause the compounding protocol to be transmitted to a robotic compounding device of the selected compounding device type; and

cause the robotic compounding device to compound the specified pharmaceutical into the delivery vehicle of the selected workflow type in accordance with the compounding protocol, wherein during compounding the specified pharmaceutical, the robotic compounding device verifies that the delivery vehicle matches the selected workflow type, transfers a correct volume of the specified pharmaceutical into the delivery vehicle, and verifies that the correct volume of the specified pharmaceutical has been transferred to the delivery vehicle.

12 . The system for pharmaceutical compounding of claim 11 , wherein the instructions cause the system to:

receive an input at the user interface that comprises instructional messages to be displayed to an operator during a compounding task.

13 . The system for pharmaceutical compounding of claim 11 , wherein the instructions cause the system to:

receive a fifth user selection of a specific delivery vehicle; and

filter the number of options to remove workflows that are not associated with the specific delivery vehicle.

14 . The system for pharmaceutical compounding of claim 11 , wherein the instructions cause the system to:

prevent incompatible compounding protocols from being created.

15 . The system for pharmaceutical compounding of claim 11 , wherein:

the one or more options comprise a plurality of available dose verification techniques.

16 . The system for pharmaceutical compounding of claim 11 , wherein:

the compounding protocol is constructed from the constructed workflow by inserting information about the particular pharmaceutical into the constructed workflow.

17 . The system for pharmaceutical compounding of claim 11 , wherein the instructions cause the system to:

calculate an estimated time for at least one compounding task; and

present the estimated time on the user interface.

18 . The system for pharmaceutical compounding of claim 11 , wherein:

the one or more options comprise a plurality of available ingredient identification techniques.

19 . The system for pharmaceutical compounding of claim 11 , wherein:

the compounding device types comprise one or both of a compounding assistance device and a robotic compounder.

20 . The system for pharmaceutical compounding of claim 19 , wherein:

the robotic compounder is specifically configured for handling dangerous drugs.

Assignments (6)
SECURITY INTEREST Recorded Feb 28, 2024
From: OMNICELL, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066703/0184 →
MERGER Recorded Jun 3, 2022
From: AESYNT HOLDINGS, INC.
To: OMNICELL, INC.
Reel/Frame 060101/0746 →
MERGER Recorded Jun 1, 2022
From: AESYNT INCORPORATED
To: AESYNT HOLDINGS, INC.
Reel/Frame 060075/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2022
From: OMNICELL, INC.
To: AESYNT INCORPORATED
Reel/Frame 059989/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2022
From: MCCUTCHAN, LARRY; MARSH, CHARLES
To: AESYNT INCORPORATED
Reel/Frame 059863/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2022
From: MAMULA, STANLEY
To: OMNICELL, INC.
Reel/Frame 059863/0949 →
Continuity (2)
Division 15827336 · Nov 30, 2017
Related Publication 20220262473A1 · Aug 18, 2022
References Cited (253)
US 6711460B1 · Reese · 2004 [cited by applicant]
US 6975924B2 · Kircher et al. · 2005 [cited by applicant]
US 7579592B2 · Kaushal · 2009 [cited by applicant]
US 7706915B2 · Mohapatra et al. · 2010 [cited by applicant]
US 8215557B1 · Reno et al. · 2012 [cited by applicant]
US 8315887B2 · Berkelhamer et al. · 2012 [cited by applicant]
US 8431404B2 · Spence et al. · 2013 [cited by applicant]
US 8554579B2 · Tribble et al. · 2013 [cited by applicant]
US 8639525B2 · Levine et al. · 2014 [cited by applicant]
US 8666780B2 · Berkelhamer et al. · 2014 [cited by applicant]
US 9069887B2 · Gupta et al. · 2015 [cited by applicant]
US 9311807B2 · Schultz et al. · 2016 [cited by applicant]
US 9375079B2 · Ranalletta et al. · 2016 [cited by applicant]
US 9959628B2 · Mutti et al. · 2018 [cited by applicant]
US 9978139B2 · Kriheli et al. · 2018 [cited by applicant]
US 10181186B2 · Kriheli · 2019 [cited by examiner]
US 10336477B2 · Perazzo et al. · 2019 [cited by applicant]
US 10596319B2 · Trovato et al. · 2020 [cited by applicant]
US 10853938B2 · Sandmann et al. · 2020 [cited by applicant]
US 10967125B2 · Trovato et al. · 2021 [cited by applicant]
US 10991264B2 · Trovato et al. · 2021 [cited by applicant]
US 11335444B2 · McCutchan et al. · 2022 [cited by applicant]
US 12017046B2 · Trovato et al. · 2024 [cited by applicant]
US 12042632B2 · Trovato et al. · 2024 [cited by applicant]
US 12343503B2 · Trovato et al. · 2025 [cited by applicant]
US 12397114B2 · Trovato et al. · 2025 [cited by applicant]
US 20010041968A1 · Hamilton · 2001 [cited by applicant]
US 20020035412A1 · Kircher · 2002 [cited by applicant]
US 20040078231A1 · Wilkes · 2004 [cited by applicant]
US 20060000470A1 · Clarke et al. · 2006 [cited by applicant]
US 20060149416A1 · Mohapatra et al. · 2006 [cited by applicant]
US 20060259195A1 · Eliuk et al. · 2006 [cited by applicant]
US 20070047980A1 · Limer et al. · 2007 [cited by applicant]
US 20070088590A1 · Berkelhamer et al. · 2007 [cited by applicant]
US 20070093935A1 · Fu · 2007 [cited by applicant]
US 20070177778A1 · Massaro · 2007 [cited by applicant]
US 20070257192A1 · Nishino et al. · 2007 [cited by applicant]
US 20080125897A1 · DiGianfilippo · 2008 [cited by applicant]
US 20080140444A1 · Karkanias et al. · 2008 [cited by applicant]
US 20080195246A1 · Tribble et al. · 2008 [cited by applicant]
US 20090154764A1 · Khan et al. · 2009 [cited by applicant]
US 20090188311A1 · Cadieux et al. · 2009 [cited by applicant]
US 20090198208A1 · Stavsky et al. · 2009 [cited by applicant]
US 20090222817A1 · Faatz et al. · 2009 [cited by applicant]
US 20100094653A1 · Tribble et al. · 2010 [cited by applicant]
US 20100097451A1 · Bruce et al. · 2010 [cited by applicant]
US 20100118130A1 · Harris et al. · 2010 [cited by applicant]
US 20100131097A1 · Young et al. · 2010 [cited by applicant]
US 20110056290A1 · Bryant et al. · 2011 [cited by applicant]
US 20110211067A1 · McKay et al. · 2011 [cited by applicant]
US 20120002042A1 · Okuma · 2012 [cited by applicant]
US 20120173254A1 · Korhnak et al. · 2012 [cited by applicant]
US 20120173255A1 · Korhnak et al. · 2012 [cited by applicant]
US 20120199239A1 · Okuda et al. · 2012 [cited by applicant]
US 20120241043A1 · Perazzo et al. · 2012 [cited by applicant]
US 20130058550A1 · Tanimoto et al. · 2013 [cited by applicant]
US 20130142406A1 · Lang et al. · 2013 [cited by applicant]
US 20130188038A1 · Tanimoto et al. · 2013 [cited by applicant]
US 20130204637A1 · Vanderveen · 2013 [cited by examiner]
US 20140062882A1 · Ozawa et al. · 2014 [cited by applicant]
US 20140156294A1 · Tribble et al. · 2014 [cited by applicant]
US 20140157731A1 · Perazzo et al. · 2014 [cited by applicant]
US 20140177932A1 · Milne et al. · 2014 [cited by applicant]
US 20140214199A1 · Utech et al. · 2014 [cited by applicant]
US 20140233797A1 · Hodder et al. · 2014 [cited by applicant]
US 20140350946A1 · Klomp · 2014 [cited by applicant]
US 20150125945A1 · Holmes et al. · 2015 [cited by applicant]
US 20150250678A1 · Eliuk et al. · 2015 [cited by applicant]
US 20150251779A1 · Tachibana et al. · 2015 [cited by applicant]
US 20150309505A1 · Popp · 2015 [cited by applicant]
US 20160001003A1 · Perazzo et al. · 2016 [cited by applicant]
US 20160071265A1 · Sandmann et al. · 2016 [cited by applicant]
US 20160073019A1 · Nowicki et al. · 2016 [cited by applicant]
US 20160092639A1 · Padmani et al. · 2016 [cited by applicant]
US 20160140315A1 · Diaz et al. · 2016 [cited by applicant]
US 20160161402A1 · Micheels et al. · 2016 [cited by applicant]
US 20160200462A1 · Kriheli et al. · 2016 [cited by applicant]
US 20160210437A1 · Padmani et al. · 2016 [cited by applicant]
US 20160232325A1 · Utech et al. · 2016 [cited by applicant]
US 20160247277A1 · Kriheli et al. · 2016 [cited by applicant]
US 20170028130A1 · Perazzo et al. · 2017 [cited by applicant]
US 20170056603A1 · Cowan et al. · 2017 [cited by applicant]
US 20170056604A1 · Cowan et al. · 2017 [cited by applicant]
US 20170286635A1 · Harshbarger, III · 2017 [cited by examiner]
US 20170333623A1 · Kamen et al. · 2017 [cited by applicant]
US 20170372034A1 · Tribble et al. · 2017 [cited by applicant]
US 20180008787A1 · Schriver et al. · 2018 [cited by applicant]
US 20180091745A1 · Holmes · 2018 [cited by applicant]
US 20180108435A1 · Brown et al. · 2018 [cited by applicant]
US 20180154088A1 · Broselow · 2018 [cited by applicant]
US 20190041318A1 · Wissmann et al. · 2019 [cited by applicant]
US 20190311490A1 · Crawford et al. · 2019 [cited by applicant]
US 20190333618A1 · Tribble · 2019 [cited by examiner]
US 20200261318A1 · Ranalletta et al. · 2020 [cited by applicant]
US 20210178071A1 · Trovato et al. · 2021 [cited by applicant]
US 20210205537A1 · Trovato et al. · 2021 [cited by applicant]
AU 2018370976 · 2019 [cited by applicant]
AU 2018374994 · 2019 [cited by applicant]
AU 2018374995 · 2019 [cited by applicant]
BR 112020008928 · 2020 [cited by applicant]
BR 112020009921 · 2020 [cited by applicant]
CA 3080903 · 2019 [cited by applicant]
CA 3081620 · 2019 [cited by applicant]
CA 3082168 · 2019 [cited by applicant]
CN 1175539A · 1998 [cited by applicant]
CN 203224706U · 2013 [cited by applicant]
CN 105593873A · 2016 [cited by applicant]
CN 102682264B · 2016 [cited by applicant]
CN 106716085A · 2017 [cited by applicant]
CN 107076606A · 2017 [cited by applicant]
CN 111433692 · 2020 [cited by applicant]
CN 111492337 · 2020 [cited by applicant]
CN 111448583 · 2021 [cited by applicant]
EP 2816346 · 2014 [cited by applicant]
EP 2983993 · 2016 [cited by applicant]
EP 3714426 · 2020 [cited by applicant]
EP 3717978 · 2020 [cited by applicant]
EP 3718066 · 2020 [cited by applicant]
FR 3007611 · 2014 [cited by applicant]
JP 0979824A · 1997 [cited by applicant]
JP 2004208842A · 2004 [cited by applicant]
JP 2006502814 · 2006 [cited by applicant]
JP 2006296912A · 2006 [cited by applicant]
JP 2007515213A · 2007 [cited by applicant]
JP 5710600B2 · 2015 [cited by applicant]
JP 2015123205 · 2015 [cited by applicant]
JP 2015167646 · 2015 [cited by applicant]
JP 2017527377A · 2017 [cited by applicant]
JP 2017534995A · 2017 [cited by applicant]
JP 2017537377 · 2017 [cited by applicant]
JP 2021503976 · 2021 [cited by applicant]
JP 2021505233 · 2021 [cited by applicant]
JP 2021505234 · 2021 [cited by applicant]
KR 20150052197A · 2015 [cited by applicant]
KR 20150069028A · 2015 [cited by applicant]
KR 20170129107A · 2017 [cited by applicant]
KR 20200093616 · 2020 [cited by applicant]
WO 03058507 · 2003 [cited by applicant]
WO 2004036481 · 2004 [cited by applicant]
WO 2004053468 · 2004 [cited by applicant]
WO WO2008057854A2 · 2008 [cited by examiner]
WO WO2011095900A1 · 2011 [cited by examiner]
WO 2011112606A1 · 2011 [cited by applicant]
WO 2012073774 · 2012 [cited by applicant]
WO 2013180127 · 2013 [cited by applicant]
WO 2014065872A1 · 2014 [cited by applicant]
WO 2014119994 · 2014 [cited by applicant]
WO 2014123147 · 2014 [cited by applicant]
WO 2014138607A1 · 2014 [cited by applicant]
WO WO2014190200A1 · 2014 [cited by examiner]
WO WO2016040334A1 · 2016 [cited by applicant]
WO 2017095702A1 · 2017 [cited by applicant]
WO 2017116961 · 2017 [cited by applicant]
WO 2019103847 · 2019 [cited by applicant]
WO 2019109048 · 2019 [cited by applicant]
WO 2019109052 · 2019 [cited by applicant]
Application No CN201880077558.6, Office Action, Mailed on Feb. 20, 2023, 6 pages (no English translation available). [cited by applicant]
U.S. Appl. No. 15/827,336, Advisory Action, Mailed on Apr. 23, 2021, 5 pages. [cited by applicant]
U.S. Appl. No. 15/827,336, “Corrected Notice of Allowability”, Mar. 11, 2022, 2 pages. [cited by applicant]
U.S. Appl. No. 15/865,038, Advisory Action, Mailed on Jan. 29, 2021, 3 pages. [cited by applicant]
U.S. Appl. No. 17/184,047, Final Office Action, Mailed on Dec. 8, 2022, 18 pages. [cited by applicant]
Application No. AU2018374994, “Notice of Acceptance”, Jun. 11, 2021, 3 pages. [cited by applicant]
Application No CN201880076771.5 , Office Action, Mailed on Oct. 24, 2022, 10 pages (no English translation). [cited by applicant]
Application No. EP18882550.9, Office Action, Mailed on Nov. 7, 2022, 9 pages. [cited by applicant]
Application No. IT102017000134813 , Office Action, Mailed on Aug. 28, 2018, 11 pages. [cited by applicant]
Application No. JP2020-529543, Notice of Allowance, Mailed on Nov. 15, 2022, 6 pages. [cited by applicant]
Application No. KR10-2020-7018537, Notice of Decision to Grant, Mailed on Nov. 29, 2022, 4 pages. [cited by applicant]
U.S. Appl. No. 17/184,047 , Notice of Allowance, Mailed on Sep. 18, 2023, 8 pages. [cited by applicant]
AU2018370976 , “First Examination Report”, May 3, 2023, 3 pages. [cited by applicant]
AU2018374995 , “First Examination Report”, Sep. 25, 2023, 5 pages. [cited by applicant]
Application No. CN201880076771.5 , Office Action, Mailed on Sep. 28, 2023, 6 pages. [cited by applicant]
Application No. CN201880077558.6 , Office Action, Mailed on Aug. 4, 2023, 4 pages. [cited by applicant]
Application No. EP18884766.9 , Office Action, Mailed on Jul. 25, 2023, 10 pages. [cited by applicant]
Application No. KR10-2020-7018009 , Office Action, Mailed on Aug. 8, 2023, 12 pages. [cited by applicant]
U.S. Appl. No. 17/209,625, “Corrected Notice of Allowability”, Feb. 2, 2023, 2 pages. [cited by applicant]
Application No. EP18880996.6, Office Action, Mailed on Jan. 31, 2023, 8 pages. [cited by applicant]
Application No. JP2020-524191, Notice of Allowance, Mailed on Feb. 1, 2023, 6 pages. [cited by applicant]
“IDS Imaging Development Systems GmbH”, data sheet for product No. UI-5481LE-M, Feb. 20, 2017, pp. 1-3. Accessed from the internet: https://en.ids-imaging.com/store/ui-5481le.html. [cited by applicant]
“Basler dart Area Scan Cameras” brochure, Jan. 2017, pp. 1-8, No. 7. Accessed from the internet: https://www.baslerweb.com/fp-1486541807/media/downloads/documents/brochure/BAS1701_dart_Broschuere_EN_SAP5052_web.pdf. [cited by applicant]
PCT/US2018/063493 received an International Search Report and Written Opinion mailed Feb. 21, 2019, 8 pages. [cited by applicant]
PCT/US2018/063500 received an International Search Report and Written Opinion mailed Feb. 7, 2019, 14 pages. [cited by applicant]
PCT/US2018/063500 received an International Preliminary Report on Patentability mailed Jun. 11, 2020, 12 pages. [cited by applicant]
U.S. Appl. No. 15/865,038 received a Non-Final Office Action mailed Mar. 8, 2019, 17 pages. [cited by applicant]
PCT/US2018/059641 received an International Search Report and Written Opinion mailed Mar. 22, 2019, 10 pages. [cited by applicant]
IT 102017000134813 received an office action mailed Apr. 9, 2018, 11 pages. [cited by applicant]
U.S. Appl. No. 15/865,038 received a Non-Final Office Action mailed Oct. 4, 2019, 18 pages. [cited by applicant]
U.S. Appl. No. 16/207,016 received a Corrected Notice of Allowance mailed Dec. 9, 2019, 2 pages. [cited by applicant]
U.S. Appl. No. 16/207,016 received a Notice of Allowance mailed Oct. 30, 2019, 9 pages. [cited by applicant]
U.S. Appl. No. 15/865,038 received a Non-Final Office Action mailed May 13, 2020, 21 pages. [cited by applicant]
U.S. Appl. No. 16/792,519 received a Non-Final Office Action mailed Sep. 4, 2020, 8 pages. [cited by applicant]
U.S. Appl. No. 15/865,038 received a Final Office Action mailed Oct. 23, 2020, 20 pages. [cited by applicant]
U.S. Appl. No. 16/792,519 received a Notice of Allowance mailed Nov. 25, 2020, 7 pages. [cited by applicant]
European patent application 18884766.9 received an Extended European Search Report, mailed Jul. 20, 2021, 10 pages. [cited by applicant]
European Application No. 18880996.6 received an Extended European Search Report, mailed Aug. 23, 2021, 10 pages. [cited by applicant]
Japan Application No. JP2020-529548 received a Final Office Action, mailed on Jan. 18, 2022, 7 pages (pp. 1-4 English translation, pp. 5-7 original document). [cited by applicant]
Korean Application No. KR10-2020-7018537 received an Office Action, mailed on Dec. 21, 2021, 14 pages (pp. 1-7 English Translation, pp. 8-14 original document). [cited by applicant]
U.S. Appl. No. 15/827,336 received a Non-Final Office Action mailed Aug. 7, 2020, 24 pages. [cited by applicant]
U.S. Appl. No. 15/827,336 received a Final Office Action mailed Jan. 25, 2021, 26 pages. [cited by applicant]
U.S. Appl. No. 15/827,336 received a Non-Final Office Action mailed Jun. 15, 2021, 24 pages. [cited by applicant]
U.S. Appl. No. 15/827,336 received a Notice of Allowance mailed Jan. 21, 2022, 8 pages. [cited by applicant]
U.S. Appl. No. 15/865,038 received a Notice of Allowance mailed on Mar. 3, 2021, 12 pages. [cited by applicant]
U.S. Appl. No. 17/184,047 received a Non-Final Office Action mailed Oct. 28, 2021, 15 pages. [cited by applicant]
U.S. Appl. No. 17/184,047 received a Final Office Action mailed Apr. 14, 2022, 15 pages. [cited by applicant]
U.S. Appl. No. 17/209,625 received a Non-Final Office Action mailed Feb. 17, 2022, 16 pages. [cited by applicant]
PCT/US2018/059641 received an International Preliminary Report on Patentability mailed Jun. 4, 2020, 9 pages. [cited by applicant]
PCT/US2018/063493 received an International Preliminary Report on Patentability mailed Jun. 11, 2020, 8 pages. [cited by applicant]
Japan patent application 2020-524191 received an office action mailed Nov. 2, 2021, 10 pages (pp. 1-6 English translation, pp. 7-10 original document). [cited by applicant]
Japan Application No. JP2020-529548 received an office action mailed on Jun. 15, 2021, 4 pages (pp. 1-4 English translation, pp. 5-8 original document). [cited by applicant]
European Application No. 18882550.9 received an Extended European Search Report mailed Jul. 6, 2021, 10 pages. [cited by applicant]
Canada Patent Application No. 3082168 received an Office Action mailed Sep. 1, 2021, 4 pages. [cited by applicant]
Australia Patent Application No. 2018374994 received a First Examination Report mailed Dec. 16, 2020, 4 pages. [cited by applicant]
U.S. Appl. No. 17/184,047 received an Advisory Action Before the Filing of an Appeal Brief mailed Jun. 27, 2022, 5 pages. [cited by applicant]
Canada Patent Application No. 3082168 received a Notice of Allowance mailed Jul. 15, 2022, 50 pages. [cited by applicant]
Japan Patent Application No. 2020-524191 received an Office Action mailed Jul. 26, 2022, 12 pages (pp. 1-7 English translation, pp. 8-12 original document). [cited by applicant]
U.S. Appl. No. 17/209,625 received a Final Office Action mailed Aug. 4, 2022, 9 pages. [cited by applicant]
Japan Patent Application No. 2020-529543 received an Office Action mailed Aug. 2, 2022, 13 pages (pp. 1-6 English translation, pp. 7-13 original document). [cited by applicant]
Japan Patent Application No. 2020-529548 received a Notice of Allowance mailed Aug. 9, 2022, 6 pages. [cited by applicant]
Korea Patent Application 10-2020-7018537 received a Final Office Action mailed Jul. 28, 2022, 8 pages (pp. 1-4 English translation, pp. 5-8 original document). [cited by applicant]
U.S. Appl. No. 17/184,047 received a Non-Final Office Action mailed Aug. 18, 2022, 16 pages. [cited by applicant]
U.S. Appl. No. 17/184,047 , “Corrected Notice of Allowability”, Mar. 7, 2024, 4 pages. [cited by applicant]
U.S. Appl. No. 17/184,047 , Notice of Allowance, Mailed on Jan. 18, 2024, 8 pages. [cited by applicant]
U.S. Appl. No. 18/168,616 , “Corrected Notice of Allowability”, Apr. 17, 2024, 2 pages. [cited by applicant]
U.S. Appl. No. 18/168,616 , Notice of Allowance, Mailed on Mar. 4, 2024, 10 pages. [cited by applicant]
AU2018370976 , “Notice of Acceptance”, May 3, 2024, 3 pages. [cited by applicant]
AU2018370976 , “Second Examination Report”, Jan. 30, 2024, 3 pages. [cited by applicant]
Application No. CA3,080,903 , Office Action, Mailed on Nov. 1, 2023, 6 pages. [cited by applicant]
Application No. CA3081620 , Office Action, Mailed on Feb. 21, 2024, 9 pages. [cited by applicant]
Application No. CN201880077558.6 , Notice of Decision to Grant, Mailed on Nov. 16, 2023, 2 pages. [cited by applicant]
Application No. EP18880996.6 , Office Action, Mailed on Dec. 8, 2023, 6 pages. [cited by applicant]
Application No. KR10-2020-7018009 , Notice of Allowance, Mailed on Feb. 22, 2024, 8 pages. [cited by applicant]
Application No. KR10-2020-7018806 , Notice of Decision to Grant, Mailed on Mar. 26, 2024, 8 pages. [cited by applicant]
Application No. KR10-2020-7018806 , Office Action, Mailed on Dec. 29, 2023, 7 pages. [cited by applicant]
Examination Report No. 2, Australian Patent Application No. 2018374995, Mailed May 8, 2024; 5 pages, IP Australia. [cited by applicant]
Notice of Acceptance, Australian Patent Application No. 2018374995, Mailed Sep. 24, 2024, 3 pages, IP Australia. [cited by applicant]
First Office Action, China Patent Application No. 201880075783.6, Mailed Jul. 17, 2024; 9 pages untranslated/4 pages translated, China National Intellectual Property Administration (CNIPA). [cited by applicant]
U.S. Appl. No. 17/184,047, “Corrected Notice of Allowability”, May 28, 2024, 4 pages. [cited by applicant]
U.S. Appl. No. 18/168,616, “Corrected Notice of Allowability”, Jun. 24, 2024, 5 pages. [cited by applicant]
U.S. Appl. No. 18/441,936, “Non-Final Office Action”, Aug. 28, 2024, 8 pages. [cited by applicant]
U.S. Appl. No. 18/441,936, “Notice of Allowance”, Feb. 26, 2025, 7 pages. [cited by applicant]
U.S. Appl. No. 18/734,678, “Non-Final Office Action”, Feb. 12, 2025, 7 pages. [cited by applicant]
U.S. Appl. No. 18/734,678, “Notice of Allowance”, Apr. 15, 2025, 5 pages. [cited by applicant]
AU2018374995, “Second Examination Report”, May 8, 2024, 5 pages. [cited by applicant]
BR1120200099279, “Office Action”, Jul. 15, 2025, 9 pages. [cited by applicant]
BR1120200099279, “Office Action”, Nov. 26, 2024, 4 pages. [cited by applicant]
CA3,081,620, “Office Action”, Apr. 22, 2025, 3 pages. [cited by applicant]
CA3080903, “Office Action”, Mar. 4, 2025, 4 pages. [cited by applicant]
CN201880075783.6, “Notice of Decision to Grant”, Dec. 11, 2024, 7 pages. [cited by applicant]
CN201880076771.5, “Office Action”, Mar. 11, 2025, 16 pages. [cited by applicant]
EP18880996.6, “Office Action”, Jul. 4, 2025, 4 pages. [cited by applicant]
EP18880996.6, “Office Action”, Nov. 18, 2024, 5 pages. [cited by applicant]
EP18882550.9, “Intention to Grant”, Aug. 7, 2025, 8 pages. [cited by applicant]
EP25166658.2, “Extended European Search Report”, Jul. 22, 2025, 9 pages. [cited by applicant]
EP18884766.9, “Summons to Attend Oral Proceedings”, Aug. 27, 2025, 11 pages. [cited by applicant]